These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 1808133)

  • 1. Evaluation of the safety and efficacy of gadoteridol injection (a low osmolal magnetic resonance contrast agent). Clinical trials report.
    DeSimone D; Morris M; Rhoda C; Lucas T; Zielonka J; Olukotun A; Carvlin M
    Invest Radiol; 1991 Nov; 26 Suppl 1():S212-6; discussion S232-5. PubMed ID: 1808133
    [No Abstract]   [Full Text] [Related]  

  • 2. Life-threatening anaphylactoid reaction after intravenous gadoteridol administration in a patient who had previously received gadopentetate dimeglumine.
    Witte RJ; Anzai LL
    AJNR Am J Neuroradiol; 1994 Mar; 15(3):523-4. PubMed ID: 8197951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse reaction to intravenous gadoteridol.
    Shellock FG; Hahn HP; Mink JH; Itskovich E
    Radiology; 1993 Oct; 189(1):151-2. PubMed ID: 8372186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Worldwide clinical safety assessment of gadoteridol injection: an update.
    Runge VM; Parker JR
    Eur Radiol; 1997; 7 Suppl 5():243-5. PubMed ID: 9370551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.
    Yuh WT; Fisher DJ; Runge VM; Atlas SW; Harms SE; Maravilla KR; Mayr NA; Mollman JE; Price AC
    AJNR Am J Neuroradiol; 1994 Jun; 15(6):1037-51. PubMed ID: 8073972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent.
    Carvlin MJ; De Simone DN; Meeks MJ
    Invest Radiol; 1992 Aug; 27 Suppl 1():S16-21. PubMed ID: 1506148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Artificial contrasting during magnetic resonance tomography].
    Sergeev PV; Panov OV; Egorova SV; Bolotova EN; Shimanovskii NL; Akhadov TA; Sviridov NK
    Vestn Rentgenol Radiol; 1997; (1):45-52. PubMed ID: 9133071
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetic behavior of gadoteridol injection.
    McLachlan SJ; Eaton S; De Simone DN
    Invest Radiol; 1992 Aug; 27 Suppl 1():S12-5. PubMed ID: 1506147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III clinical evaluation of gadoteridol injection: experience in pediatric neuro-oncologic MR imaging.
    Debatin JF; Nadel SN; Gray L; Friedman HS; Trotter P; Hockenberger B; Oakes WJ
    Pediatr Radiol; 1992; 22(2):93-8. PubMed ID: 1501959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonionic contrast media open new paths for MRI.
    D'Agincourt L
    Diagn Imaging (San Franc); 1990 May; 12(5):90-6. PubMed ID: 10183698
    [No Abstract]   [Full Text] [Related]  

  • 11. Review of the use of high-dose gadoteridol in the magnetic resonance evaluation of central nervous system tumors.
    Yuh WT; Fisher DJ; Mayr-Yuh NA; Tali ET; Nguyen HD; Gao F; Ehrhardt JC
    Invest Radiol; 1992 Aug; 27 Suppl 1():S39-44. PubMed ID: 1506152
    [No Abstract]   [Full Text] [Related]  

  • 12. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
    Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
    Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerance after intravenous administration of 0.3 mmol/kg Gd-DTPA. Results of a randomized, controlled clinical trial.
    Niendorf HP; Haustein J; Louton T; Beck W; Laniado M
    Invest Radiol; 1991 Nov; 26 Suppl 1():S221-3; discussion S232-5. PubMed ID: 1808134
    [No Abstract]   [Full Text] [Related]  

  • 14. Intravenous MRI contrast enhancement of inflammatory synovium: a dose study.
    Oliver C; Watt I
    Br J Rheumatol; 1996 Dec; 35 Suppl 3():31-5. PubMed ID: 9010087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosage of gadoteridol and adverse reactions relative to gadopentetate.
    Hieronim DE; Kanal E; Swanson DP
    Am J Health Syst Pharm; 1995 Nov; 52(22):2556-9. PubMed ID: 8590239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Safety of Gadoteridol, Representative of the Macrocyclic Class of Gadolinium-Based Contrast Agents.
    Runge VM
    J Magn Reson Imaging; 2020 Mar; 51(3):869-870. PubMed ID: 31614049
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety of gadoteridol injection: U.S. clinical trial experience.
    Olukotun AY; Parker JR; Meeks MJ; Lucas MA; Fowler DR; Lucas TR
    J Magn Reson Imaging; 1995; 5(1):17-25. PubMed ID: 7696805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatal Anaphylaxis Associated With the Gadolinium-Based Contrast Agent Gadoteridol (ProHance).
    Takahashi S; Takada A; Saito K; Hara M; Yoneyama K; Nakanishi H
    J Investig Allergol Clin Immunol; 2015; 25(5):366-7. PubMed ID: 26727767
    [No Abstract]   [Full Text] [Related]  

  • 19. [Anaphylactoid reaction caused by intravenous gadopentetate dimeglumine in magnetic resonance].
    Campos A; Aznar L; Alamar R; Castelló JV
    Med Clin (Barc); 1996 Feb; 106(5):197. PubMed ID: 8684023
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis.
    Yuh WT; Tali ET; Nguyen HD; Simonson TM; Mayr NA; Fisher DJ
    AJNR Am J Neuroradiol; 1995 Feb; 16(2):373-80. PubMed ID: 7726087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.